Variant sequences: the new frontier in sequence IP

A variant sequence is typically a naturally-occurring molecule, most frequently protein, which has been modified in order to impart desired characteristics such as improved stability under anticipated use conditions, or increased activity. Optimising sequences and, of course, the associated IP rights, span most areas of biotechnology.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

Moderna VP and regulatory expert moves to private practice

2 February 2026 The third European life sciences hire in recent months brings in-house regulatory expertise from Moderna in Munich.

Careers

Crowell adds tech partner with in-house and private practice expertise

2 February 2026 The seasoned IP leader has left biotech GRAIL to expand the firm’s capabilities in life sciences, technology, and AI in California.

Careers

Winston & Strawn and Taylor Wessing UK seal ‘powerhouse’ merger

30 January 2026 Transatlantic ‘powerhouse’ Winston Taylor is set to launch in May 2026, with a particular focus on technology, life sciences and transatlantic services.

More features

Fed Circ overturns PTAB decision in $83.4m DNA case

Novartis win blocks generics relitigating $7.8bn heart drug patent

Rooted in rights: Lessons from plant patent infringement and invalidity cases

Skinny labels, big stakes: SCOTUS lines up the case of the year

Speciality pharma firm stumbles on bid to enforce Belbuca ruling

Senior USPTO solicitor steps into private practice

Goodwin targets transatlantic patent work with London hire

Bayer secures key Denmark ruling as Xarelto faces expiry pressure

Variant sequences: the new frontier in sequence IP

More on this story

Editor's picks

Editor's picks

More features